cilta-cel as a potential new soc for r/r multiple myeloma: insights from the cartitude-4 trial
Published 3 months ago • 89 plays • Length 3:54Download video MP4
Download video MP3
Similar videos
-
2:33
latest results from the cartitude-2 trial of cilta-cel in progressive multiple myeloma
-
2:17
cilta-cel: a paradigm shift in the treatment of multiple myeloma
-
1:17
efficacy & safety of standard of care cilta-cel in r/r multiple myeloma
-
1:54
cilta-cel vs standard of care in functional high-risk myeloma: findings from cartitude-4
-
2:25
cartitude-5: vrd cilta-cel or rd in newly diagnosed multiple myeloma
-
4:04
the future of myeloma treatment and the possibility of cure
-
5:10
what is multiple myeloma? - animated
-
9:25
mgus diagnosis: a step-by-step approach
-
3:02
real-world safety and efficacy of cilta-cel in r/r multiple myeloma
-
1:47
cilta-cel in earlier lines of therapy for r/r multiple myeloma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
2:31
cilta-cel achieves deep and durable responses for r/r multiple myeloma
-
4:33
cilta-cel elicits deep and durable responses in patients with multiple myeloma with early relapse
-
1:35
cilta-cel vs ide-cel for r/r multiple myeloma: making the decision in clinical practice
-
2:21
cilta-cel versus soc in functionally high-risk myeloma with one prior therapy
-
1:59
the growing importance of celmods in the treatment of r/r multiple myeloma
-
1:30
cartitude-1: promising initial results of cilta-cel for myeloma
-
5:44
cilta-cel in r/r myeloma: preliminary results from cartitude-1
-
1:33
choosing between ide-cel and cilta-cel for the treatment of r/r multiple myeloma
-
0:36
the recent expanded fda approval of cilta-cel and ide-cel into earlier lines of myeloma treatment
-
0:50
car-t in multiple myeloma: cilta-cel & ide-cel
-
3:54
highlights in multiple myeloma from ash 2021: cilta-cel, bispecific antibodies & disease biology